Stockreport

Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024 [Yahoo! Finance]

Vigil Neuroscience, Inc.  (VIGL) 
PDF differentiated neuroprotective profile and ability to favorably tune microglia activation WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. [Read more]